The estimated Net Worth of Phillip Schwartz is at least $1.8 Million dollars as of 20 January 2022. Phillip Schwartz owns over 10,000 units of Entera Bio Ltd stock worth over $1,081,190 and over the last 3 years he sold ENTX stock worth over $0. In addition, he makes $722,014 as President of Research and Development at Entera Bio Ltd.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Phillip Schwartz ENTX stock SEC Form 4 insiders trading
Phillip has made over 1 trades of the Entera Bio Ltd stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ENTX stock worth $25,300 on 20 January 2022.
The largest trade he's ever made was buying 10,000 units of Entera Bio Ltd stock on 20 January 2022 worth over $25,300. On average, Phillip trades about 10,000 units every 0 days since 2022. As of 20 January 2022 he still owns at least 607,410 units of Entera Bio Ltd stock.
You can see the complete history of Phillip Schwartz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Phillip Schwartz biography
Dr. Phillip Schwartz Ph.D. serves as President of Research and Development of the Company. Dr. Schwartz has previously served as our Chief Executive Officer from our inception in 2010 to August 2019. Dr. Schwartz has more than 20 years of biotech and pharmaceutical industry experience. He previously served as the manager of clinical affairs at Endo Pharmaceuticals plc from 2005 to 2010 and at Serono from 2002 to 2005, and held multiple positions in medical affairs, business development and clinical trial development at each of Endo Pharmaceuticals plc and Serono. He has also worked as an external consultant for a number of venture capital firms. He has also consulted privately and served as an associate of Health Advances, LLC for more than 20 large biotech and pharmaceutical companies from 2000 to 2002. He has multiple publications in tier one peer-reviewed journals and has presented papers at numerous international conferences. He has also worked in the neurobiology laboratory of Nobel Laureate Professor Torsten Wiesel of the Rockefeller University. Dr. Schwartz holds a B.A. in psychology and architecture from Columbia University, an M.Sc. in immunology while studying under Professor Irun Cohen at the Weizmann Institute, and a Ph.D. in neurobiology/development/oncology from Harvard Medical School. In addition to his scientific training, Dr. Schwartz completed numerous clinical courses as part of his program at Harvard Medical School. After completing his Ph.D., Dr. Schwartz was a fellow in pediatric oncology at the Dana Farber Cancer Institute and an officer of Harvard University Medical School.
What is the salary of Phillip Schwartz?
As the President of Research and Development of Entera Bio Ltd, the total compensation of Phillip Schwartz at Entera Bio Ltd is $722,014. There are no executives at Entera Bio Ltd getting paid more.
How old is Phillip Schwartz?
Phillip Schwartz is 58, he's been the President of Research and Development of Entera Bio Ltd since 2019. There are 9 older and 8 younger executives at Entera Bio Ltd. The oldest executive at Entera Bio Ltd is Gerald Lieberman, 73, who is the Independent Chairman of the Board.
What's Phillip Schwartz's mailing address?
Phillip's mailing address filed with the SEC is KIRYAT HADASSAH,, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, L3, 9112002.
Insiders trading at Entera Bio Ltd
Over the last 3 years, insiders at Entera Bio Ltd have traded over $0 worth of Entera Bio Ltd stock and bought 467,822 units worth $484,536 . The most active insiders traders include Gerald M Lieberman, Miranda Jayne Toledano, and Sean Ellis. On average, Entera Bio Ltd executives and independent directors trade stock every 32 days with the average trade being worth of $36,205. The most recent stock trade was executed by Haya Taitel on 12 January 2024, trading 9,500 units of ENTX stock currently worth $9,405.
What does Entera Bio Ltd's logo look like?
Complete history of Phillip Schwartz stock trades at Entera Bio Ltd
Entera Bio Ltd executives and stock owners
Entera Bio Ltd executives and other stock owners filed with the SEC include:
-
Phillip Schwartz,
President of Research and Development -
Gerald Lieberman,
Independent Chairman of the Board -
Arthur Santora,
Chief Medical Officer -
Dr. Phillip Schwartz Ph.D.,
Exec. VP, Pres of R&D and Director -
Roger Garceau,
Chief Executive Officer, Director -
Hillel Galitzer,
Chief Operating Officer -
Dr. Hillel Galitzer,
Chief Operating Officer -
Dr. Arthur C. Santora II, M.D., Ph.D.,
Chief Medical Officer -
Kiryat Hadassah,
IR Contact Officer -
Miranda Toledano,
Independent Director -
Gerald Ostrov,
Independent Director -
Faith Charles,
Independent Director -
Yonatan Malca,
Director -
Sean Ellis,
Director -
Zeev Bronfeld,
Director -
Jonathan Lieber,
Chief Financial Officer - U.S.-based -
Dana Yaacov-Garbeli,
Chief Financial Officer -
Dr. Roger J. Garceau,
Chief Devel. Advisor & Director -
Ramesh Ratan,
U.S. Chief Financial Officer -
Dana Yaacov-Garbeli CPA,
Chief Financial Officer -
Dr. Spiros Jamas,
CEO & Director -
Haya Taitel,
Director -
Ramesh Ratan,
U.S.based CFO -
Spiros Jamas,
Chief Executive Officer -
Ron Mayron,
Director